$8.63 Million in Sales Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter

Wall Street analysts expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce sales of $8.63 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Conatus Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $6.13 million and the highest estimate coming in at $10.00 million. Conatus Pharmaceuticals reported sales of $8.80 million in the same quarter last year, which would suggest a negative year over year growth rate of 1.9%. The company is expected to issue its next quarterly earnings results after the market closes on Friday, March 8th.

On average, analysts expect that Conatus Pharmaceuticals will report full year sales of $34.81 million for the current fiscal year, with estimates ranging from $32.30 million to $36.18 million. For the next year, analysts anticipate that the company will post sales of $41.87 million, with estimates ranging from $24.25 million to $80.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Conatus Pharmaceuticals.

Get Conatus Pharmaceuticals alerts:

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research lowered Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, February 19th. ValuEngine lowered Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, December 11th. SunTrust Banks dropped their price target on Conatus Pharmaceuticals to $12.00 and set a “buy” rating for the company in a research report on Thursday, December 6th. Roth Capital restated a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Wednesday, February 13th. Finally, Oppenheimer set a $10.00 price target on Conatus Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, December 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $8.50.

Shares of CNAT stock traded down $0.04 during trading hours on Friday, reaching $1.97. The company had a trading volume of 504,400 shares, compared to its average volume of 548,650. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.39 and a quick ratio of 2.39. The firm has a market capitalization of $60.83 million, a PE ratio of -3.23 and a beta of 3.41. Conatus Pharmaceuticals has a 12-month low of $1.15 and a 12-month high of $7.95.

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in Conatus Pharmaceuticals by 75.7% during the 2nd quarter. Bank of America Corp DE now owns 140,687 shares of the biotechnology company’s stock valued at $602,000 after buying an additional 60,604 shares in the last quarter. BlackRock Inc. grew its holdings in Conatus Pharmaceuticals by 13.4% during the 3rd quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock valued at $9,419,000 after buying an additional 191,287 shares in the last quarter. Artal Group S.A. purchased a new position in Conatus Pharmaceuticals during the 3rd quarter valued at approximately $2,900,000. Virtu Financial LLC grew its holdings in Conatus Pharmaceuticals by 94.6% during the 3rd quarter. Virtu Financial LLC now owns 25,860 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 12,572 shares in the last quarter. Finally, Hikari Power Ltd purchased a new position in Conatus Pharmaceuticals during the 4th quarter valued at approximately $289,000. Institutional investors and hedge funds own 30.63% of the company’s stock.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Recommended Story: Why are analyst ratings important in trading stocks?

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Leave a Reply

Your email address will not be published. Required fields are marked *